Zalicus Inc (ZLCS) 1.18 $ZLCS
EPIRUS Biopharmaceuticals Reports Third Quarter Results and Provides Corporate Update
Business Wire - Mon Nov 10, 3:30PM CST
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ZLCS: 1.18 (+0.03), EPRS: 3.95 (-0.27)
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors
Business Wire - Tue Jul 15, 10:49AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will serve on its board of directors. The board, which was reconstituted today following the company's merger with Zalicus Inc. (Zalicus, NASDAQ: ZLCS), also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu.
CRME: 8.89 (+0.36), TRVN: 5.56 (-0.07), AVNR: 13.13 (-0.01), ZLCS: 1.18 (+0.03), IRWD: 13.13 (-0.36), CBST: 70.52 (-1.22), EPRS: 3.95 (-0.27)
EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS)
Business Wire - Tue Jul 15, 10:47AM CDT
--EPIRUS reconstitutes Board of Directors to include Mark H.N. Corrigan, M.D., Julie H. McHugh, William Hunter, M.D., Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu
ZLCS: 1.18 (+0.03), EPRS: 3.95 (-0.27)
Zalicus and Epirus Agree Zalicus Stockholders to Own 19% of Combined Company Post-Merger
Business Wire - Wed Jun 25, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS) ("Zalicus"
, and Epirus Biopharmaceuticals, Inc. ("Epirus" agreed today that Zalicus stockholders will own 19% of the combined company post-merger. Pursuant to its merger agreement with Epirus Biopharmaceuticals, Inc., the percentage of the combined company that Zalicus stockholders will own as of the closing of the merger was subject to adjustment at the closing based on the level of Zalicus' net cash as of a determination date prior to the closing. Based on Zalicus' current level of net cash, both companies have agreed that stockholders of Zalicus will own approximately 19% of the combined company and current Epirus equityholders will own approximately 81% of the Company following the merger.
ZLCS: 1.18 (+0.03)
Anabios Licenses Sodium Channel Blocking Pain Therapeutic Portfolio from Zalicus
PRWeb - Thu Jun 19, 3:16AM CDT
AnaBios Corporation announced today the licensing of a portfolio of novel preclinical, sodium channel blocking pain therapeutics from Zalicus Inc. The agreement is aimed at accelerating the successful development of new selective sodium channel blockers by employing AnaBios' proprietary Phase X™ technology. Under the terms of the agreement, AnaBios acquires an exclusive license for all development and commercialization rights related to Zalicus' Nav1.7 portfolio of compounds, having a projected commercial market of at least $1.5B annually. In addition, Zalicus will be eligible for future clinical and regulatory milestone payments from AnaBios and the two companies will share in royalty payments based upon any potential future product sales.
ZLCS: 1.18 (+0.03)
Zalicus Licenses Sodium Channel Pain Modulation Program
Business Wire - Wed Jun 18, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of net sales on any future products resulting from this license.
ZLCS: 1.18 (+0.03)
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics
PR Newswire - Tue Jun 17, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Geron Corporation (NASDAQ: GERN), Zalicus Inc. (NASDAQ: ZLCS), Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3775-100free.
PGNX: 6.33 (-0.12), NWBO: 5.79 (-0.13), ZLCS: 1.18 (+0.03), GERN: 2.76 (+0.45), TGTX: 14.03 (+0.16)
Short Squeeze Starting in Zalicus (ZLCS) According to WealthMakers.com Report
M2 - Fri Jun 13, 6:54AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a research report on Zalicus (NASDAQ: ZLCS). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $1.49 and the projected fundamental valuation of $6.60.
ZLCS: 1.18 (+0.03)
Why Zalicus (ZLCS) Stock Is Surging Today
at The Street - Thu Jun 12, 10:10AM CDT
Zalicus (ZLCS) surged Thursday after Epirus Switzerland announced clinical data from a Phase 3 study of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis.
ZLCS: 1.18 (+0.03)
Zalicus to Present at AACR 2014 Annual Meeting
Business Wire - Tue Apr 01, 7:30AM CDT
Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research (AACR) 2014 Annual Meeting which takes place April 5-9, 2014 in San Diego, CA. These preclinical data, which were generated in separate studies by leveraging the Zalicus combination High-throughput screening (cHTS(TM)) technology platform, demonstrate the potential to identify (or highlight) synergistic activity of the Eisai nontaxane eribulin and the Sanofi antibody drug conjugate SAR3419, through drug combinations.
ZLCS: 1.18 (+0.03)
Zalicus Reports Financial Results for the Fourth Quarter and Year-End 2013
Business Wire - Thu Mar 13, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2013.
ZLCS: 1.18 (+0.03)
Canadian Forex Review: C$ Strengthens
Commodity News Service Canada - Commodity News Service Canada, Inc. - Wed Feb 12, 3:44PM CST
The Canadian dollar strengthened against the US dollar on Wednesday amid positive Chinese trade data, analysts said.
RNN: 0.68 (-0.01), ZLCS: 1.18 (+0.03), CHYR: 2.71 (+0.01), CATM: 37.39 (-0.53), UAL: 56.10 (-0.66)
OTC Signal Daily Stock Watch - Zalicus Inc. (Nasdaq: ZLCS)
WorldStockWire - Thu Sep 12, 2:15AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
ZLCS: 1.18 (+0.03)
Zalicus Inc reports launch of Phase 1b clinical trial of Z944 for the treatment of pain
M2 - Tue Sep 10, 8:49AM CDT
Biopharmaceutical company Zalicus Inc (Nasdaq Capital Market:ZLCS) revealed on Monday the initiation of a Phase 1b clinical study of Z944 in an experimental clinical model of neuropathic pain using Laser-Evoked Potentials (LEP).
ZLCS: 1.18 (+0.03)
Investors look to Lighten Up on Shares of Zalicus, Shares Down 6.2% (ZLCS)
Comtex SmarTrend(R) - Mon Sep 09, 11:45AM CDT
Zalicus (NASDAQ:ZLCS) is one of today's worst performing penny stocks, down 6.2% to $0.79 on 1.0x average daily volume. Thus far today, Zalicus has traded 2.8 million shares, vs. average volume of 2.8 million shares per day. The stock has underperformed the Dow (-6.2% to the Dow's 0.8%) and underperformed the S&P 500 (-6.2% to the S&P's 0.7%) during today's trading.
ZLCS: 1.18 (+0.03)
Zalicus Initiates Phase 1b Clinical Study of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, for the Treatment of Pain
Business Wire - Mon Sep 09, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market:ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has initiated a Phase 1b clinical study with Z944, its novel oral T-type calcium channel blocker, in an experimental clinical model of neuropathic pain using Laser-Evoked Potentials (LEP). Results from the LEP study are expected in the fourth quarter 2013.
ZLCS: 1.18 (+0.03)
Hot Stock: Zalicus, Shares Gain 14.3% (ZLCS)
Comtex SmarTrend(R) - Tue Sep 03, 10:16AM CDT
Zalicus (NASDAQ:ZLCS) is one of today's best performing penny stocks, up 14.3% to $0.81 on 1.3x average daily volume. Zalicus has traded 2.9 million shares thus far today, vs. average volume of 2.1 million shares per day. The stock has outperformed the Dow (14.3% to the Dow's 0.6%) and outperformed the S&P 500 (14.3% to the S&P's 0.9%) during today's trading.
ZLCS: 1.18 (+0.03)
Zalicus to Present at the Rodman & Renshaw 15th Annual Global Investment Conference
Business Wire - Tue Sep 03, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Zalicus management will present at the Rodman & Renshaw 15th Annual Global Investment Conference at 10:25 a.m. ET on Monday, September 9, 2013 in New York. Interested parties may access a live webcast of the presentation by visiting the Zalicus website at www.zalicus.com. The webcast will be archived on the Zalicus website following the event.
ZLCS: 1.18 (+0.03)
Zalicus Completes Patient Enrollment in Two Phase 2 Clinical Studies of Z160 for Chronic Neuropathic Pain
Business Wire - Tue Sep 03, 7:00AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has completed patient enrollment in two Phase 2 clinical studies of Z160 for chronic neuropathic pain indications including lumbosacral radiculopathy and postherpetic neuralgia. Top-line results of both studies are expected in the fourth quarter of 2013. Z160 is a first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker in development for chronic neuropathic pain.
ZLCS: 1.18 (+0.03)
Stock to Watch: Zalicus Up 5.5% (ZLCS)
Comtex SmarTrend(R) - Fri Aug 30, 12:50PM CDT
Zalicus (NASDAQ:ZLCS) is one of today's best performing penny stocks, up 5.5% to $0.71 on 1.1x average daily volume. Zalicus has traded 2.2 million shares thus far today, vs. average volume of 2.1 million shares per day. The stock has outperformed the Dow (5.9% to the Dow's -0.2%) and outperformed the S&P 500 (5.9% to the S&P's -0.3%) during today's trading.
ZLCS: 1.18 (+0.03)
EPIRUS Biopharmaceuticals Reports Third Quarter Results and Provides Corporate Update
Business Wire - Mon Nov 10, 3:30PM CST
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ZLCS: 1.18 (+0.03), EPRS: 3.95 (-0.27)
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors
Business Wire - Tue Jul 15, 10:49AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will serve on its board of directors. The board, which was reconstituted today following the company's merger with Zalicus Inc. (Zalicus, NASDAQ: ZLCS), also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu.
CRME: 8.89 (+0.36), TRVN: 5.56 (-0.07), AVNR: 13.13 (-0.01), ZLCS: 1.18 (+0.03), IRWD: 13.13 (-0.36), CBST: 70.52 (-1.22), EPRS: 3.95 (-0.27)
EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS)
Business Wire - Tue Jul 15, 10:47AM CDT
--EPIRUS reconstitutes Board of Directors to include Mark H.N. Corrigan, M.D., Julie H. McHugh, William Hunter, M.D., Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu
ZLCS: 1.18 (+0.03), EPRS: 3.95 (-0.27)
Zalicus and Epirus Agree Zalicus Stockholders to Own 19% of Combined Company Post-Merger
Business Wire - Wed Jun 25, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS) ("Zalicus"
, and Epirus Biopharmaceuticals, Inc. ("Epirus" agreed today that Zalicus stockholders will own 19% of the combined company post-merger. Pursuant to its merger agreement with Epirus Biopharmaceuticals, Inc., the percentage of the combined company that Zalicus stockholders will own as of the closing of the merger was subject to adjustment at the closing based on the level of Zalicus' net cash as of a determination date prior to the closing. Based on Zalicus' current level of net cash, both companies have agreed that stockholders of Zalicus will own approximately 19% of the combined company and current Epirus equityholders will own approximately 81% of the Company following the merger. ZLCS: 1.18 (+0.03)
Anabios Licenses Sodium Channel Blocking Pain Therapeutic Portfolio from Zalicus
PRWeb - Thu Jun 19, 3:16AM CDT
AnaBios Corporation announced today the licensing of a portfolio of novel preclinical, sodium channel blocking pain therapeutics from Zalicus Inc. The agreement is aimed at accelerating the successful development of new selective sodium channel blockers by employing AnaBios' proprietary Phase X™ technology. Under the terms of the agreement, AnaBios acquires an exclusive license for all development and commercialization rights related to Zalicus' Nav1.7 portfolio of compounds, having a projected commercial market of at least $1.5B annually. In addition, Zalicus will be eligible for future clinical and regulatory milestone payments from AnaBios and the two companies will share in royalty payments based upon any potential future product sales.
ZLCS: 1.18 (+0.03)
Zalicus Licenses Sodium Channel Pain Modulation Program
Business Wire - Wed Jun 18, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of net sales on any future products resulting from this license.
ZLCS: 1.18 (+0.03)
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics
PR Newswire - Tue Jun 17, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Geron Corporation (NASDAQ: GERN), Zalicus Inc. (NASDAQ: ZLCS), Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3775-100free.
PGNX: 6.33 (-0.12), NWBO: 5.79 (-0.13), ZLCS: 1.18 (+0.03), GERN: 2.76 (+0.45), TGTX: 14.03 (+0.16)
Short Squeeze Starting in Zalicus (ZLCS) According to WealthMakers.com Report
M2 - Fri Jun 13, 6:54AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a research report on Zalicus (NASDAQ: ZLCS). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $1.49 and the projected fundamental valuation of $6.60.
ZLCS: 1.18 (+0.03)
Why Zalicus (ZLCS) Stock Is Surging Today
at The Street - Thu Jun 12, 10:10AM CDT
Zalicus (ZLCS) surged Thursday after Epirus Switzerland announced clinical data from a Phase 3 study of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis.
ZLCS: 1.18 (+0.03)
Zalicus to Present at AACR 2014 Annual Meeting
Business Wire - Tue Apr 01, 7:30AM CDT
Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research (AACR) 2014 Annual Meeting which takes place April 5-9, 2014 in San Diego, CA. These preclinical data, which were generated in separate studies by leveraging the Zalicus combination High-throughput screening (cHTS(TM)) technology platform, demonstrate the potential to identify (or highlight) synergistic activity of the Eisai nontaxane eribulin and the Sanofi antibody drug conjugate SAR3419, through drug combinations.
ZLCS: 1.18 (+0.03)
Zalicus Reports Financial Results for the Fourth Quarter and Year-End 2013
Business Wire - Thu Mar 13, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2013.
ZLCS: 1.18 (+0.03)
Canadian Forex Review: C$ Strengthens
Commodity News Service Canada - Commodity News Service Canada, Inc. - Wed Feb 12, 3:44PM CST
The Canadian dollar strengthened against the US dollar on Wednesday amid positive Chinese trade data, analysts said.
RNN: 0.68 (-0.01), ZLCS: 1.18 (+0.03), CHYR: 2.71 (+0.01), CATM: 37.39 (-0.53), UAL: 56.10 (-0.66)
OTC Signal Daily Stock Watch - Zalicus Inc. (Nasdaq: ZLCS)
WorldStockWire - Thu Sep 12, 2:15AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
ZLCS: 1.18 (+0.03)
Zalicus Inc reports launch of Phase 1b clinical trial of Z944 for the treatment of pain
M2 - Tue Sep 10, 8:49AM CDT
Biopharmaceutical company Zalicus Inc (Nasdaq Capital Market:ZLCS) revealed on Monday the initiation of a Phase 1b clinical study of Z944 in an experimental clinical model of neuropathic pain using Laser-Evoked Potentials (LEP).
ZLCS: 1.18 (+0.03)
Investors look to Lighten Up on Shares of Zalicus, Shares Down 6.2% (ZLCS)
Comtex SmarTrend(R) - Mon Sep 09, 11:45AM CDT
Zalicus (NASDAQ:ZLCS) is one of today's worst performing penny stocks, down 6.2% to $0.79 on 1.0x average daily volume. Thus far today, Zalicus has traded 2.8 million shares, vs. average volume of 2.8 million shares per day. The stock has underperformed the Dow (-6.2% to the Dow's 0.8%) and underperformed the S&P 500 (-6.2% to the S&P's 0.7%) during today's trading.
ZLCS: 1.18 (+0.03)
Zalicus Initiates Phase 1b Clinical Study of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, for the Treatment of Pain
Business Wire - Mon Sep 09, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market:ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has initiated a Phase 1b clinical study with Z944, its novel oral T-type calcium channel blocker, in an experimental clinical model of neuropathic pain using Laser-Evoked Potentials (LEP). Results from the LEP study are expected in the fourth quarter 2013.
ZLCS: 1.18 (+0.03)
Hot Stock: Zalicus, Shares Gain 14.3% (ZLCS)
Comtex SmarTrend(R) - Tue Sep 03, 10:16AM CDT
Zalicus (NASDAQ:ZLCS) is one of today's best performing penny stocks, up 14.3% to $0.81 on 1.3x average daily volume. Zalicus has traded 2.9 million shares thus far today, vs. average volume of 2.1 million shares per day. The stock has outperformed the Dow (14.3% to the Dow's 0.6%) and outperformed the S&P 500 (14.3% to the S&P's 0.9%) during today's trading.
ZLCS: 1.18 (+0.03)
Zalicus to Present at the Rodman & Renshaw 15th Annual Global Investment Conference
Business Wire - Tue Sep 03, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Zalicus management will present at the Rodman & Renshaw 15th Annual Global Investment Conference at 10:25 a.m. ET on Monday, September 9, 2013 in New York. Interested parties may access a live webcast of the presentation by visiting the Zalicus website at www.zalicus.com. The webcast will be archived on the Zalicus website following the event.
ZLCS: 1.18 (+0.03)
Zalicus Completes Patient Enrollment in Two Phase 2 Clinical Studies of Z160 for Chronic Neuropathic Pain
Business Wire - Tue Sep 03, 7:00AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has completed patient enrollment in two Phase 2 clinical studies of Z160 for chronic neuropathic pain indications including lumbosacral radiculopathy and postherpetic neuralgia. Top-line results of both studies are expected in the fourth quarter of 2013. Z160 is a first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker in development for chronic neuropathic pain.
ZLCS: 1.18 (+0.03)
Stock to Watch: Zalicus Up 5.5% (ZLCS)
Comtex SmarTrend(R) - Fri Aug 30, 12:50PM CDT
Zalicus (NASDAQ:ZLCS) is one of today's best performing penny stocks, up 5.5% to $0.71 on 1.1x average daily volume. Zalicus has traded 2.2 million shares thus far today, vs. average volume of 2.1 million shares per day. The stock has outperformed the Dow (5.9% to the Dow's -0.2%) and outperformed the S&P 500 (5.9% to the S&P's -0.3%) during today's trading.
ZLCS: 1.18 (+0.03)
